Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855802 | 1.00 | HSD17B10 (0.56) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL855801 | 1.00 | HSD17B10 (0.56) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL857222 | 0.95 | HSD17B10 (0.52) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL3758643 | 0.95 | HSD17B10 (0.52) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL859184 | 0.95 | HSD17B10 (0.52) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL856413 | 0.94 | HSD17B10 (0.60) | HSD17B10KDM4EGAATGFBR1GFER | |
| SCHEMBL859649 | 0.92 | HSD17B10 (0.53) | HSD17B10KDM4EGAAIDO1TDO2 | |
| SCHEMBL858471 | 0.87 | HSD17B10 (0.50) | HSD17B10KDM4EGAATGFBR1GFER | |
| SCHEMBL859140 | 0.86 | HSD17B10 (0.54) | HSD17B10KDM4EGAAGFERKMT2A | |
| SCHEMBL856401 | 0.84 | HSD17B10 (0.69) | HSD17B10KDM4EGAAIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | HSD17B10 1254/4885KDM4E 610/4885GAA 752/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | HSD17B10 1066/4885KDM4E 760/4885GAA 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.